Reduce Trial-and-Error Prescribing for Mental Health Treatment

Improve lives and reduce costs when it matters most.

Pharmacogenomics (PGx)—how a person’s unique DNA impacts her/his response to medications—is the solution to many of today’s healthcare challenges.

Prescription drug use to treat mental health conditions is increasing during COVID-19.1

  • As of mid-July 2020, 53% of adults in the U.S. reported that their mental health has been negatively impacted.2
  • Mental health spending rose to $225 billion in 2019—an increase of 52% in the past decade3—a number likely to increase.
  • Approximately 60 FDA-approved medications used to treat mental health concerns are impacted by genetics.

Medication Impact

PGx accounts for drug-gene interactions to improve drug safety, predict responders vs non-responders, and identify those at risk of developing serious or life-threatening adverse drug events with certain medications.

Adverse Drug Events (ADEs)

ADEs can range from nausea, fatigue, and weight gain to extreme instances of muscle pain, seizures, and even death.

.

Personalized Treatment

Tailoring treatment based on a patient’s genetics can improve efficacy and reduce potential toxicity. PGx has been demonstrated to improve outcomes in cancer, depression, pain management, and many other conditions.4-9

Reduce Trial-and-Error Prescribing for Mental Health Treatment

Power In KnowingTM

Coriell Life Sciences (CLS) is a precision medicine company using pharmacogenomics to improve lives, reduce healthcare costs, and simplify decision-making.

Download this overview for a Case Study in Smarter Healthcare and learn how we work with Employer and Payer Organizations, Physicians, and Providers.

Get in Touch

For more information, connect with us today.

    *required

    1America’s State of Mind Report. https://www.express-scripts.com/corporate/americas-state-of-mind-report

    2The Implications of COVID-19 for Mental Health and Substance Use. https://www.kff.org/coronavirus-covid-19/issue-brief/the-implications-of-covid-19-for-mental-health-and-substance-use/

    3Mental Health Spending Now & After the Pandemic https://openminds.com/market-intelligence/executive-briefings/mental-health-spending-now-after-the-pandemic/

    4Romero Lagunes, M.L.; Vera Badillo, F.E. Design and Implementing Pharmacogenomics Study in Cancer. Adv Exp Med Biol 2019, 1168, 43-77, doi:10.1007/978-3-030-24100-1_4. 

    5Jha, M.K.; Trivedi, M.H. Pharmacogenomics and Biomarkers of Depression. Handb Exp Pharmacol 2019, 250, 101-113, doi:10.1007/164_2018_171. 

    6Morales-Espinosa, D.; Garcia-Roman, S.; Karachaliou, N.; Rosell, R. Pharmacogenomics in the treatment of lung cancer: an update. Pharmacogenomics 2015, 16, 1751-1760, doi:10.2217/pgs.15.99. 

    7Roden, D.M. Cardiovascular pharmacogenomics: current status and future directions. J Hum Genet 2016, 61, 79-85, doi:10.1038/jhg.2015.78. 

    8Sleder, A.T.; Kalus, J.; Lanfear, D.E. Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner. J Cardiovasc Pharmacol Ther 2016, 21, 20-26, 429 doi:10.1177/1074248415590196. 

    9Bondy, B. Pharmacogenomics in depression and antidepressants. Dialogues in clinical neuroscience 2005, 7, 223-230.

    Last Updated: January 4, 2021